A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects

Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation

As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit

Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels

Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1

Subjects will be randomised to receive a single dose of placebo